Preparation and application of novel interferon alpha-2b wet tissue

A technology of interferon α, -2b, applied in skin care preparations, medical preparations containing active ingredients, cosmetic preparations, etc., can solve the problem of loss of biological activity, no interferon α-2b wet wipes, interference Loss of activity of α-2b and other problems

Active Publication Date: 2015-04-22
SHANGHAI HUAXIN HIGH BIOTECH
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because interferon and other biologically active cytokines are easily affected by factors such as temperature, oxygen, light, adsorption, enzymes and microbial activities in aqueous solution, they lose their biological activity.
And contain most of water in the wet tissue, easily make the activity of interferon α-2b lose, so the biological activity problem of interferon α-2b is the technical problem that needs to be solved in the preparation of interferon α-2b wet tissue, also just Because of the existence of this problem, there is no interferon alpha-2b wet tissue in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of novel interferon alpha-2b wet tissue
  • Preparation and application of novel interferon alpha-2b wet tissue
  • Preparation and application of novel interferon alpha-2b wet tissue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1, novel interferon alpha-2b wet tissue

[0044] A novel interferon α-2b wet tissue is composed of a medicinal solution and a non-woven fabric bearing the medicinal solution, wherein the medicinal solution contains:

[0045] Recombinant Human Interferon α-2b 8mg

[0046] Sodium Propylene Glycol Alginate 2mg

[0047] Purified water 90mg

[0048] The non-woven fabric adopts spunlace non-woven fabric, and the specifications meet: the ingredients are viscose and polyester, and the content of viscose fiber is between 30-60%, and the weight of the non-woven fabric used is in the range of 40-60g / m 2 .

[0049] The preparation method of this wet tissue comprises the following steps:

[0050] 1) Weighing: Weigh recombinant human interferon α-2b, propylene glycol sodium alginate and purified water according to the above dosage;

[0051] 2) Mixing: add an appropriate amount of purified water to recombinant human interferon α-2b and propylene glycol sodium alginate,...

Embodiment 2

[0054] Embodiment 2, novel interferon alpha-2b wet tissue

[0055] A novel interferon α-2b wet tissue is composed of a medicinal solution and a non-woven fabric bearing the medicinal solution, wherein the medicinal solution contains:

[0056] Recombinant Human Interferon α-2b 8mg

[0057] Sodium alginate 2mg

[0058] Purified water 90mg

[0059] The non-woven fabric is made of all-cotton non-woven fabric, and the specifications meet: the composition is natural cotton fiber, and the weight of the non-woven fabric used is in the range of 40-60g / m 2 .

[0060] The preparation method of this wet tissue comprises the following steps:

[0061] 1) Weighing: Weigh recombinant human interferon α-2b, sodium alginate and purified water in proportion;

[0062] 2) Mixing: add an appropriate amount of purified water to recombinant human interferon α-2b and sodium alginate, stir until dissolved, then add the remaining purified water under stirring, and stir until completely dissolved to...

Embodiment 3

[0065] Embodiment 3, novel interferon alpha-2b wet tissue

[0066] A novel interferon α-2b wet tissue is composed of a medicinal solution and a non-woven fabric bearing the medicinal solution, wherein the medicinal solution contains:

[0067] Interferon alpha-2b 10mg

[0068] Propylene Glycol Potassium Alginate 1mg

[0069] Purified water 89mg

[0070] The non-woven fabric is made of full viscose non-woven fabric, and the specifications meet: the composition is viscose fiber, and the weight of the non-woven fabric used is in the range of 40-60g / m 2 .

[0071] The preparation method of this wet tissue comprises the following steps:

[0072] 1) Weighing: Weigh interferon α-2b, propylene glycol potassium alginate and purified water in proportion;

[0073] 2) Mixing: add an appropriate amount of purified water to interferon α-2b and propylene glycol potassium alginate, stir until dissolved, then add the remaining purified water while stirring, and stir until completely dissol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of wet tissues and application thereof and specifically relates to preparation and application of a novel interferon alpha-2b wet tissue. The novel interferon alpha-2b wet tissue provided by the invention comprises medicine liquid and a carrier carrying the medicine liquid, wherein the medicine liquid contains interferon alpha-2b, a protein stabilizer and water, and the mass ratio of the protein stabilizer to interferon alpha-2b is 1: (4-20), preferably 1: (4-10) and more preferably 1: 4. The invention solves the problem of bioactivity of interferon alpha-2b in the interferon alpha-2b wet tissue and creates a wet tissue containing interferon alpha-2b; and furthermore, the wet tissue containing interferon alpha-2b can be applied to auxiliary treatment of viral infection type skin diseases, such as herpes labialis, herpes zoster, genital herpes, genital warts and the like, and can well solve various disadvantages of various conventional methods for treating viral infection type diseases.

Description

technical field [0001] The invention belongs to the technical field of wet tissue and its application, and in particular relates to the preparation and application of a novel interferon alpha-2b wet tissue. Background technique [0002] At present, the wet wipes and disinfectant wipes sold in the domestic market all contain chemical ingredients, such as bleaching powder, bromogeramine, iodophor, peracetic acid or glyoxal, although they have certain disinfection and sterilization effects. , but it is irritating to the skin and even toxic, so it is not suitable for damaged skin and baby's delicate skin. If the content of chemical disinfection ingredients is reduced in order to reduce irritation, the disinfection effect of wet wipes will be weakened, and the growth of bacteria cannot be effectively inhibited. At the same time, the residues of chemical components will pollute the environment. There is an urgent need for a wet wipe that can effectively clean and disinfect and w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/21A61K9/70A61P31/12A61P31/20A61P31/14A61P31/22A61P37/04A61K8/02A61K8/97A61K8/92A61K8/64A61Q19/10
Inventor 刘慧钟京谕李冠英王鉴王阳
Owner SHANGHAI HUAXIN HIGH BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap